Boundless Bio Inc. (BOLD)

Over the past six months, Boundless Bio's stock has been influenced by participation in conferences, FDA acceptance of the IND application for BBI-940, financial results announcements, and analyst ratings. Key events include participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, FDA acceptance of the IND application for BBI-940, updates on the POTENTIATE clinical trial, and participation in the Piper Sandler 37th Annual Healthcare Conference. H.C. Wainwright reiterated a "Buy" rating on the stock with a $4 target. The company announced portfolio prioritization and runway extension, which was followed by a 15.58% decrease in stock price. Piper Sandler, Leerink Partners, and Guggenheim initiated coverage with "Overweight," "Outperform," and "Buy" ratings, respectively. Guggenheim downgraded the stock from "Buy" to "Neutral". The stock debuted at $16 per share on March 28, 2024, but dropped to $2.88 by August 2024. As of February 3, 2026, the stock price was $1.06.

Boundless Bio's products and services are not subject to typical seasonal demand fluctuations. Demand for its therapeutic candidates is driven by the prevalence of oncogene-amplified cancers and the progression of its clinical trials. Success in clinical trials and regulatory approvals would be the primary drivers of future demand.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing novel cancer therapeutics that target extrachromosomal DNA (ecDNA) in oncogene-amplified tumors. The company's major products and platforms include BBI-355, an oral CHK1 inhibitor in Phase 1/2 clinical trials; BBI-825, an oral RNR inhibitor being evaluated in combination with BBI-355; BBI-940, a novel Kinesin degrader program progressing towards IND submission; ECHO, an ecDNA diagnostic test; and the Spyglass Platform, used to identify druggable targets in oncogene-amplified cancers.

Boundless Bio, Inc. is headquartered in San Diego, California, United States. The company's clinical trial activities are typically global or national in scope.

Boundless Bio's brand reputation has been shaped by its clinical development progress and financial performance. Positive events include the FDA's acceptance of the IND application for BBI-940 and participation in healthcare investor conferences and scientific presentations. Negative events include the significant drop in stock price, layoffs due to sluggish enrollment in trials, and downgrades by analysts.

Boundless Bio, Inc. has 60 institutional owners and shareholders holding a total of 9,938,583 shares. Major institutional owners include FMR LLC, Nextech Invest, Ltd., Citadel Advisors LLC, Sectoral Asset Management Inc, Vanguard Group Inc, Wellington Management Group LLP, Stonepine Capital Management, LLC, Alyeska Investment Group, L.P., Redmile Group, LLC, and Renaissance Technologies LLC. Insider ownership stands at 28.92%.